Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 125.92 Billion KRW | -34.04% |
| 2022 | 190.9 Billion KRW | 4.61% |
| 2021 | 182.49 Billion KRW | 7.56% |
| 2020 | 169.65 Billion KRW | 0.87% |
| 2019 | 168.19 Billion KRW | -13.4% |
| 2018 | 194.22 Billion KRW | 28.84% |
| 2017 | 150.74 Billion KRW | 8.75% |
| 2016 | 138.61 Billion KRW | -2.47% |
| 2015 | 142.13 Billion KRW | 0.31% |
| 2014 | 141.68 Billion KRW | 8.33% |
| 2013 | 130.79 Billion KRW | -11.34% |
| 2012 | 147.52 Billion KRW | 45.75% |
| 2011 | 101.21 Billion KRW | -43.96% |
| 2010 | 180.62 Billion KRW | 5.74% |
| 2009 | 170.81 Billion KRW | 5.71% |
| 2008 | 161.57 Billion KRW | 3.8% |
| 2007 | 155.67 Billion KRW | 13.2% |
| 2006 | 137.52 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 42.59 Billion KRW | 15.66% |
| 2024 Q1 | 34.39 Billion KRW | 37.46% |
| 2024 Q2 | 36.83 Billion KRW | 7.09% |
| 2023 Q1 | 37.23 Billion KRW | -39.44% |
| 2023 FY | 125.92 Billion KRW | -34.04% |
| 2023 Q2 | 43.42 Billion KRW | 16.61% |
| 2023 Q3 | 20.25 Billion KRW | -53.36% |
| 2023 Q4 | 25.02 Billion KRW | 23.54% |
| 2022 Q2 | 42.86 Billion KRW | 16.13% |
| 2022 Q1 | 36.91 Billion KRW | -31.57% |
| 2022 FY | 190.9 Billion KRW | 4.61% |
| 2022 Q3 | 49.64 Billion KRW | 15.8% |
| 2022 Q4 | 61.48 Billion KRW | 23.85% |
| 2021 FY | 182.49 Billion KRW | 7.56% |
| 2021 Q1 | 36.85 Billion KRW | -25.49% |
| 2021 Q3 | 47.82 Billion KRW | 9.03% |
| 2021 Q2 | 43.86 Billion KRW | 19.02% |
| 2021 Q4 | 53.94 Billion KRW | 12.8% |
| 2020 Q1 | 37.8 Billion KRW | -26.43% |
| 2020 Q3 | 40.34 Billion KRW | -4.02% |
| 2020 Q4 | 49.46 Billion KRW | 22.59% |
| 2020 Q2 | 42.03 Billion KRW | 11.2% |
| 2020 FY | 169.65 Billion KRW | 0.87% |
| 2019 Q3 | 39.73 Billion KRW | -3.51% |
| 2019 Q4 | 51.38 Billion KRW | 29.3% |
| 2019 Q1 | 35.88 Billion KRW | -14.91% |
| 2019 FY | 168.19 Billion KRW | -13.4% |
| 2019 Q2 | 41.18 Billion KRW | 14.78% |
| 2018 FY | 194.22 Billion KRW | 28.84% |
| 2018 Q3 | 76.26 Billion KRW | 88.12% |
| 2018 Q4 | 42.17 Billion KRW | -44.7% |
| 2018 Q2 | 40.54 Billion KRW | 15.03% |
| 2018 Q1 | 35.24 Billion KRW | -10.98% |
| 2017 Q3 | 38.35 Billion KRW | -1.47% |
| 2017 Q1 | 33.86 Billion KRW | 2.16% |
| 2017 Q2 | 38.92 Billion KRW | 14.95% |
| 2017 FY | 150.74 Billion KRW | 8.75% |
| 2017 Q4 | 39.58 Billion KRW | 3.22% |
| 2016 Q3 | 34.72 Billion KRW | -8.22% |
| 2016 FY | 138.61 Billion KRW | -2.47% |
| 2016 Q2 | 37.83 Billion KRW | 14.97% |
| 2016 Q4 | 33.15 Billion KRW | -4.53% |
| 2016 Q1 | 32.9 Billion KRW | -12.71% |
| 2015 Q4 | 37.69 Billion KRW | 4.85% |
| 2015 Q2 | 35.41 Billion KRW | 7.12% |
| 2015 FY | 142.13 Billion KRW | 0.31% |
| 2015 Q3 | 35.95 Billion KRW | 1.51% |
| 2015 Q1 | 33.06 Billion KRW | -5.82% |
| 2014 Q4 | 35.1 Billion KRW | -1.4% |
| 2014 Q2 | 35.17 Billion KRW | -1.73% |
| 2014 Q1 | 35.79 Billion KRW | 8.14% |
| 2014 Q3 | 35.6 Billion KRW | 1.22% |
| 2014 FY | 141.68 Billion KRW | 8.33% |
| 2013 Q4 | 33.1 Billion KRW | 0.98% |
| 2013 FY | 130.79 Billion KRW | -11.34% |
| 2013 Q2 | 31.8 Billion KRW | -3.93% |
| 2013 Q1 | 33.1 Billion KRW | -17.11% |
| 2013 Q3 | 32.78 Billion KRW | 3.07% |
| 2012 Q2 | 37.44 Billion KRW | 25.29% |
| 2012 Q3 | 40.25 Billion KRW | 7.51% |
| 2012 FY | 147.52 Billion KRW | 45.75% |
| 2012 Q1 | 29.88 Billion KRW | 0.0% |
| 2012 Q4 | 39.93 Billion KRW | -0.79% |
| 2011 Q3 | 36.45 Billion KRW | -12.66% |
| 2011 Q2 | 41.73 Billion KRW | -19.29% |
| 2011 Q1 | 51.71 Billion KRW | 17.47% |
| 2011 FY | 101.21 Billion KRW | -43.96% |
| 2010 FY | 180.62 Billion KRW | 5.74% |
| 2010 Q3 | 43.18 Billion KRW | 3.55% |
| 2010 Q4 | 44.02 Billion KRW | 1.94% |
| 2010 Q2 | 41.7 Billion KRW | -3.41% |
| 2010 Q1 | 43.17 Billion KRW | 0.93% |
| 2009 Q4 | 42.77 Billion KRW | -4.85% |
| 2009 FY | 170.81 Billion KRW | 5.71% |
| 2009 Q1 | - KRW | -100.0% |
| 2009 Q2 | 39.89 Billion KRW | 0.0% |
| 2009 Q3 | 44.95 Billion KRW | 12.68% |
| 2008 FY | 161.57 Billion KRW | 3.8% |
| 2008 Q2 | 38.65 Billion KRW | 0.0% |
| 2008 Q3 | 41.46 Billion KRW | 7.29% |
| 2008 Q4 | 38.36 Billion KRW | -7.48% |
| 2008 Q1 | - KRW | -100.0% |
| 2007 Q2 | 35.9 Billion KRW | 0.0% |
| 2007 Q4 | 40.92 Billion KRW | 3.39% |
| 2007 FY | 155.67 Billion KRW | 13.2% |
| 2007 Q3 | 39.58 Billion KRW | 10.25% |
| 2006 FY | 137.52 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 8.222% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 88.876% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 80.276% |
| HANDOK Inc. | 522.74 Billion KRW | 75.91% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | 6.977% |
| Yuhan Corporation | 1858.98 Billion KRW | 93.226% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 81.034% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -142.379% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 91.553% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | 6.657% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 66.015% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -42.141% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 25.736% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 43.896% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 8.222% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -61.336% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 16.643% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -44.143% |
| JW Holdings Corporation | 928.07 Billion KRW | 86.431% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 79.038% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 92.457% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 83.177% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 37.108% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 30.335% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 35.864% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 82.664% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 8.222% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 91.685% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 90.844% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 83.177% |
| Yuhan Corporation | 1858.98 Billion KRW | 93.226% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 84.154% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 46.391% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 78.82% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 83.177% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 56.893% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 54.855% |
| CKD Bio Corp. | 160.35 Billion KRW | 21.468% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 76.103% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 65.127% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 45.342% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 37.108% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 85.686% |
| Boryung Corporation | 859.62 Billion KRW | 85.351% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 66.015% |
| JW Lifescience Corporation | 206.86 Billion KRW | 39.124% |